Stay updated with breaking news from Magforce Ag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from MagForce AG, MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Investegate announcements from MagForce AG, MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann Further results of the pivotal study 2a confirm expectations, market approval in 2021 still in prospect, price target of EUR 11.00 and BUY rating confirmed After MagForce AG announced the successful completion of stage 2a of the pivotal study for the treatment of prostate cancer in the USA in February 2021, the company has published additional, more concrete results on this study phase in a recent company announcement. After further analysis of the results of the 10 patients included in phase 2a, only minimal side effects were ob...
MagForce AG MagForce AG enters into an Agreement with Apeiron Investment Group Ltd. to issue Convertible Notes in the total amount of EUR 2.5 million DGAP-Ad-hoc: MagForce AG / Key word(s): Financing MagForce AG enters into an Agreement with Apeiron Investment Group Ltd. to issue Convertible Notes in the total amount of EUR 2.5 million 10-March-2021 / 20:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Disclosure of a...
Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann Successful completion of Phase 2a trial for the treatment of prostate cancer; market approval expected in 2021; forecasts and BUY price target confirmed MagForce AG has announced the successful completion of Stage 2a of the pivotal trial for the treatment of prostate cancer in the United States. As expected, the treatment group of 10 patients experienced only minimal treatment-related side effects, comparable to those of the first study phase. Prior to the start of the second study phase, MagForce AG had established a streamlined...